TTRX (TTRX) reported G&A of $1.14M in Q1 2026.

How has TTRX's G&A changed year-over-year?

TTRX's G&A increased by 202.5% year-over-year, from $375.74K to $1.14M.

Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.

TTRX TTRX G&A

G&A at other companies

Celldex TherapeuticsCLDX

$11.45M+5.8%

Kymera TherapeuticsKYMR

$20.36M+25.1%

PVL

Palvella TherapeuticsPVLA

$5.52M+45.4%

Other financials

Income statement

See full

Operating income-$1.2M-224%

Net income-$971.0K-196%

EPS (diluted)-$0.03-200%

Balance sheet

See full

Cash & equivalents$11.2M+613%

Total debt$6.0M—

Total equity$6.1M+647%

Total assets$18.6M—

Cash flow

See full

Operating cash flow-$1.6M-448%

Valuation

See full

Market cap$217.45M-17.7%

Enterprise value$212.24M—

Returns & leverage

See full

Return on equity-118.8%—

Debt / equity1×—

Current ratio2.2×—

Where this comes from

Reported directly by TTRX in its filing.

Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.

The official record: TTRX’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about TTRX's g&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is TTRX's G&A?: TTRX (TTRX) reported G&A of $1.14M in Q1 2026.
How has TTRX's G&A changed year-over-year?: TTRX's G&A increased by 202.5% year-over-year, from $375.74K to $1.14M.
What does G&A mean?: Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.